Self-asssembling nanostructure vaccines
US-11771755-B2 · Oct 3, 2023 · US
Polypeptides for use in self-assembling protein nanostructures
US2023159595A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2023159595-A1 |
| Application number | US-202217934343-A |
| Country | US |
| Kind code | A1 |
| Filing date | Sep 22, 2022 |
| Priority date | Nov 3, 2014 |
| Publication date | May 25, 2023 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.
First claim
Opening claim text (preview).
1 .- 20 . (canceled) 21 . A self-assembling icosahedral protein nanostructure, comprising: 20 trimeric components having 3-fold symmetry, each trimeric component comprising 3 first subunits, wherein each first subunit comprises a polypeptide having a polypeptide sequence that is at least 80% identical to SEQ ID NO: 7 or 29-31; and 12 pentameric components having 5-fold symmetry, each pentameric component comprising 5 second subunits, wherein each second subunit comprises a polypeptide having a polypeptide sequence that is at least 80% identical to SEQ ID NO: 8 or 32-34. 22 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is at least 90% identical to SEQ ID NO: 7 or 29-31; and wherein the polypeptide sequence of each second subunit is at least 90% identical to SEQ ID NO: 8 or 32-34. 23 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is at least 95% identical to SEQ ID NO: 7 or 29-31; and wherein the polypeptide sequence of each second subunit is at least 95% identical to SEQ ID NO: 8 or 32-34. 24 . The nanostructure of claim 23 , wherein the trimeric components and the pentameric components form an I53 icosahedral architecture. 25 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 7; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 8. 26 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 7; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 32. 27 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 7; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 33. 28 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 7; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 34. 29 . The nanostructure of claim 28 , wherein the trimeric components and the pentameric components form an I53 icosahedral architecture. 30 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 29; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 8. 31 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 29; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 32. 32 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 29; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 33. 33 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 29; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 34. 34 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 30; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 8. 35 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 30; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 32. 36 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 30; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 33. 37 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 30; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 34. 38 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 31; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 8. 39 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 31; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 32. 40 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 31; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 33. 41 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 31; and wherein the polypeptide sequence of each second subunit is SEQ ID NO: 34. 42 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is at least 95% identical to SEQ ID NO: 7. 43 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is at least 95% identical to SEQ ID NO: 29. 44 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is at least 95% identical to SEQ ID NO: 30. 45 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is at least 95% identical to SEQ ID NO: 31. 46 . The nanostructure of claim 21 , wherein the polypeptide sequence of each second subunit is at least 95% identical to SEQ ID NO: 8. 47 . The nanostructure of claim 21 , wherein the polypeptide sequence of each second subunit is at least 95% identical to SEQ ID NO: 32. 48 . The nanostructure of claim 21 , wherein the polypeptide sequence of each second subunit is at least 95% identical to SEQ ID NO: 33. 49 . The nanostructure of claim 21 , wherein the polypeptide sequence of each second subunit is at least 95% identical to SEQ ID NO: 34. 50 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 7. 51 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 29. 52 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 30. 53 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is SEQ ID NO: 31. 54 . The nanostructure of claim 21 , wherein the polypeptide sequence of each second subunit is SEQ ID NO: 8. 55 . The nanostructure of claim 21 , wherein the polypeptide sequence of each second subunit is SEQ ID NO: 32. 56 . The nanostructure of claim 21 , wherein the polypeptide sequence of each second subunit is SEQ ID NO: 33. 57 . The nanostructure of claim 21 , wherein the polypeptide sequence of each second subunit is SEQ ID NO: 34. 58 . The nanostructure of claim 21 , wherein the polypeptide sequence of each first subunit is identical to SEQ ID NO: 7 or 29-31 at at least 3 of interface amino acid positions 25, 29, 33, 54, and 57; and wherein the polypeptide sequence of each second subunit is identical to SEQ ID NO: 8 or 32-34 at at least 3 of interface amino acid positions 24, 28, 36, 124, 125, 127, 128, 129, 131, 132, 133, 135, and 139. 59 . The nanostructure of claim 23 , wherein the polypeptide sequence of each first subunit is identical to SEQ ID NO: 7 or 29-31 at at least 3 of interface amino acid positions 25, 29, 33, 54, and 57; and wherein the polypeptide sequence of each second subunit is identical to SEQ ID NO: 8 o
Assignees
Inventors
Classifications
- C07K14/00Primary
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2023159595A1 cover?
- Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.
- Who is the assignee on this patent?
- Univ Washington
- What technology area does this patent fall under?
- Primary CPC classification C07K14/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu May 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).